Cargando…

Chimeric antigen receptor‐T cell therapies: The changing landscape

Detalles Bibliográficos
Autores principales:	Sengsayadeth, Salyka M., Dholaria, Bhagirathbhai R., Savani, Bipin N., Oluwole, Olalekan O.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176045/ https://www.ncbi.nlm.nih.gov/pubmed/35844302 http://dx.doi.org/10.1002/jha2.340

Ejemplares similares

Role of bridging therapy during chimeric antigen receptor T cell therapy
por: Bhaskar, Shakthi T., et al.
Publicado: (2021)

Overview of approved CAR‐T therapies, ongoing clinical trials, and its impact on clinical practice
por: Sengsayadeth, Salyka, et al.
Publicado: (2021)

CAR T cell therapy in solid tumors: A review of current clinical trials
por: Patel, Urvi, et al.
Publicado: (2021)

Challenges and Advances in Chimeric Antigen Receptor Therapy for Acute Myeloid Leukemia
por: Marvin-Peek, Jennifer, et al.
Publicado: (2022)

Chimeric antigen receptor T‐cell therapy: Challenges and framework of outpatient administration
por: Gatwood, Katie S., et al.
Publicado: (2021)

Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic
por: Bachanova, Veronika, et al.
Publicado: (2020)

Posttransplant maintenance therapy in multiple myeloma: the changing landscape
por: Sengsayadeth, S, et al.
Publicado: (2017)

Securing the graft during pandemic: are we ready for cryopreservation for all?
por: Dholaria, Bhagirathbhai, et al.
Publicado: (2020)

New‐onset posttransplant diabetes mellitus after haploidentical hematopoietic cell transplantation with posttransplant cyclophosphamide
por: Mangan, Brendan L., et al.
Publicado: (2020)

Six Month Freedom from Treatment Failure is an Important Endpoint for Acute Graft-Versus-Host Disease Clinical Trials
por: Sengsayadeth, Salyka, et al.
Publicado: (2013)

Intestinal Strongyloides causing peritoneal eosinophilia in peritoneal dialysis
por: Saha, Sharmeela, et al.
Publicado: (2012)

The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook
por: Zhang, Hao, et al.
Publicado: (2022)

High Sensitivity Troponin T and NT-proBNP in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell Therapy
por: Hu, Jiun-Ruey, et al.
Publicado: (2021)

Therapeutic implication of chimeric antigen receptor T-cell therapy for head and neck squamous cell carcinoma
por: Pazhani, Jayanthi, et al.
Publicado: (2023)

Development of molecular and pharmacological switches for chimeric antigen receptor T cells
por: Wu, Bill X., et al.
Publicado: (2019)

Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome
por: Bhaskar, Shakthi T., et al.
Publicado: (2022)

Chimeric antigen receptor T-cell therapy
por: Burge, Cale, et al.
Publicado: (2023)

Current Advances and Hurdles in Chimeric Antigen Receptor Technology
por: McComb, Scott, et al.
Publicado: (2020)

Chimeric antigen receptor T cell therapies for thoracic cancers—challenges and opportunities
por: Chan, Jack D., et al.
Publicado: (2020)

Chimeric Antigen Receptor T Cell Therapy in Hematology
por: Ataca, Pınar, et al.
Publicado: (2015)

Chimeric Antigen Receptor T-Cell Therapy and Hematopoiesis
por: Reinhardt, Bryanna, et al.
Publicado: (2023)

Chimeric Antigen Receptor Therapy for B-cell Malignancies
por: Porter, David L, et al.
Publicado: (2011)

Chimeric antigen receptor T-cell therapy for solid tumors
por: Newick, Kheng, et al.
Publicado: (2016)

Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
por: Dai, Hanren, et al.
Publicado: (2016)

Chimeric antigen receptor T cell therapy for multiple myeloma
por: Hasegawa, Kana, et al.
Publicado: (2019)

Mechanisms of failure of chimeric antigen receptor T-cell therapy
por: Li, Xiaoqing, et al.
Publicado: (2019)

Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma
por: Hosen, Naoki
Publicado: (2019)

Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer
por: Sur, Daniel, et al.
Publicado: (2020)

Chimeric antigen receptor T cell therapies for multiple myeloma
por: Wu, Chao, et al.
Publicado: (2019)

Chimeric antigen receptor T-cell therapy for multiple myeloma
por: Wang, Zehua, et al.
Publicado: (2022)

Chimeric antigen receptor T-cell therapy for T-ALL and AML
por: Wei, Wenwen, et al.
Publicado: (2022)

Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy
por: Han, Xiao, et al.
Publicado: (2019)

Allogeneic Chimeric Antigen Receptor Therapy in Lymphoma
por: Khurana, Arushi, et al.
Publicado: (2022)

Paving the Way Towards Universal Chimeric Antigen Receptor Therapy in Cancer Treatment: Current Landscape and Progress
por: Zhang, Yixi, et al.
Publicado: (2020)

Post-CD19 Chimeric Antigen Receptor T-Cell Therapy Cytomegalovirus Retinitis
por: Bin dokhi, Haifa, et al.
Publicado: (2022)

Humanized Chimeric Antigen Receptor (CAR) T cells
por: Kozani, Pouya Safarzadeh, et al.
Publicado: (2021)

Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
por: Pang, Yanyu, et al.
Publicado: (2018)

Is Chimeric Antigen Receptor T-cell Therapy the Future of Autoimmunity Management?
por: Tahir, Amber
Publicado: (2018)

Increasing the safety and efficacy of chimeric antigen receptor T cell therapy
por: Li, Hua, et al.
Publicado: (2017)

Switching on the green light for chimeric antigen receptor T‐cell therapy
por: Mardiana, Sherly, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5i8pc4l7ln2gpe6jgv9stdtn5u